Hypoxia promotes both resistance to conventional cancer therapies and tumor progression by creating microenvironment enriched in poorly differentiated tumor cells and undifferentiated stromal cells, including MSCs [7], in part, through stabilization of the transcription activator, “hypoxia-inducible factor-1 alpha (HIF-1α)” in tumor and stromal cells [8]. This evidence concerns the gene HIF1A and neoplasm.